| 2.1 0.02 (0.96%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.47  |
1-year : | 2.6 |
| Resists | First : | 2.12 |
Second : | 2.23 |
| Pivot price | 2.12 |
|||
| Supports | First : | 1.95 |
Second : | 1.62 |
| MAs | MA(5) : | 2.12 |
MA(20) : | 2.12  |
| MA(100) : | 2.31 |
MA(250) : | 2.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.7 |
D(3) : | 62.7 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 4.59 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMRA ] has closed above bottom band by 20.4%. Bollinger Bands are 46.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 2.02 - 2.03 | 2.03 - 2.04 |
| Close: | 2.05 - 2.08 | 2.08 - 2.1 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Tue, 14 Apr 2026
Up to 5 million Canadians have IBS; Biomerica brings inFoods north - Stock Titan
Mon, 13 Apr 2026
Biomerica IBS test gets $300 Medicare rate, reports pain relief - Stock Titan
Mon, 13 Apr 2026
Biomerica 10-Q: Revenue $0.99M, EPS $(0.44) for Q3 ended Feb 28, 2026 - TradingView — Track All Markets
Mon, 13 Apr 2026
Biomerica (BMRA) revenue falls 22% as losses persist and going concern risk disclosed - Stock Titan
Thu, 09 Apr 2026
Press Releases about Biomerica, Inc. - Common Stock (Nasdaq:BMRA) - FinancialContent
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | -90.4 % |
| Operating Margin | -113.5 % |
| Return on Assets (ttm) | -49.5 % |
| Return on Equity (ttm) | -84.4 % |
| Qtrly Rev. Growth | -26 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 1.47 |
| EBITDA (p.s.) | -1.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 1.37 |
| Price to Sales | 1.39 |
| Price to Cash Flow | -2.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|